Tactile Systems Technology Inc. (TCMD)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1027838 · fiscal year ends in Dec
Closing price $24.32 on 29 Oct 2026; 52-week range $15.07 to $33.05.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $350.3M
- Revenue growth
- 17.2%
- Net income, last twelve months
- $24.9M
- Earnings per share
- $1.08
- Gross margin
- 76.8%
- Operating margin
- 10.0%
- Net margin
- 7.1%
- Free cash flow
- $26.8M
- Return on equity
- 11.1%
- Market value
- $552.1M
- Price to earnings
- 22.5x
- Cash
- $69.9M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 22.7M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $329.5M | $29.3M | $19.1M | $0.82 | $40.4M | 10-K filed 17 Feb 2026 |
| FY2024 | 31 Dec 2024 | $293.0M | $22.2M | $17.0M | $0.70 | $38.3M | 10-K filed 18 Feb 2025 |
| FY2023 | 31 Dec 2023 | $274.4M | $18.0M | $28.5M | $1.23 | $33.5M | 10-K filed 20 Feb 2024 |
| FY2022 | 31 Dec 2022 | $246.8M | -$12.8M | -$17.9M | -$0.89 | $3.4M | 10-K filed 21 Feb 2023 |
| FY2021 | 31 Dec 2021 | $208.1M | -$1.8M | -$11.8M | -$0.60 | $528.0K | 10-K filed 23 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $85.7M | $7.8M | $0.34 |
| Q1 FY2026 | 31 Mar 2026 | $75.3M | -$1.8M | -$0.08 |
| Q4 FY2025 | 31 Dec 2025 | $103.6M | $10.6M | $0.46 |
| Q3 FY2025 | 30 Sep 2025 | $85.8M | $8.2M | $0.36 |
| Q2 FY2025 | 30 Jun 2025 | $78.9M | $3.2M | $0.14 |
| Q1 FY2025 | 31 Mar 2025 | $61.3M | -$3.0M | -$0.13 |
| Q4 FY2024 | 31 Dec 2024 | $85.6M | $9.7M | $0.40 |
| Q3 FY2024 | 30 Sep 2024 | $73.1M | $5.2M | $0.21 |
Company events
The newest 8-K filings of 87 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 10 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Jul 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 7 May 2026 | 8-K | Shareholder vote, Bylaws or fiscal year change | 5.03, 5.07, 9.01 |
| 4 May 2026 | 8-K | Results | 2.02, 9.01 |
| 9 Mar 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 17 Feb 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 3 Nov 2025 | 8-K | Results, Other events | 2.02, 8.01, 9.01 |
| 4 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 9 May 2025 | 8-K | Leadership change, Shareholder vote | 5.02, 5.07, 9.01 |
| 5 May 2025 | 8-K | Results | 2.02, 9.01 |
| 18 Feb 2025 | 8-K | Results | 2.02, 9.01 |
| 13 Jan 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 225 held.
| Filed | Form | Period |
|---|---|---|
| 10 Aug 2026 | 10-Q | 30 Jun 2026 |
| 10 Aug 2026 | 8-K | 10 Aug 2026 |
| 13 Jul 2026 | 8-K | 13 Jul 2026 |
| 1 Jun 2026 | SD | – |
| 7 May 2026 | 8-K | 6 May 2026 |
| 4 May 2026 | S-8 | – |
| 4 May 2026 | 10-Q | 31 Mar 2026 |
| 4 May 2026 | 8-K | 4 May 2026 |
| 25 Mar 2026 | ARS | 31 Dec 2025 |
| 25 Mar 2026 | DEFA14A | – |
| 25 Mar 2026 | DEF 14A | 6 May 2026 |
| 10 Mar 2026 | PRE 14A | 6 May 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 10 Aug 2026 | Dodd Sheri Louise, Chief Executive Officer | Sale outside a trading plan | 10,978 | $29.44 | $323.2K | 232,907 | 12 Aug 2026 |
| 11 May 2026 | Birkemeyer Elaine M., CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 4,631 | $24.49 | $113.4K | 130,188 | 13 May 2026 |
| 24 Feb 2026 | Dodd Sheri Louise, Chief Executive Officer | Sale outside a trading plan | 10,993 | $28.94 | $318.1K | 243,885 | 26 Feb 2026 |
| 24 Feb 2026 | Birkemeyer Elaine M., CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 7,701 | $28.94 | $222.9K | 134,819 | 26 Feb 2026 |
| 24 Feb 2026 | Burns Kristie, Sr. VP Mktg & Clinical Affairs | Sale outside a trading plan | 6,246 | $28.94 | $180.8K | 82,581 | 26 Feb 2026 |
| 23 Feb 2026 | Birkemeyer Elaine M., CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 5,322 | $28.28 | $150.5K | 142,716 | 24 Feb 2026 |
| 23 Feb 2026 | Birkemeyer Elaine M., CHIEF FINANCIAL OFFICER | Sale outside a trading plan | 196 | $28.69 | $5.6K | 142,520 | 24 Feb 2026 |
| 23 Feb 2026 | Dodd Sheri Louise, Chief Executive Officer | Sale outside a trading plan | 14,703 | $28.28 | $415.8K | 255,415 | 24 Feb 2026 |
| 23 Feb 2026 | Dodd Sheri Louise, Chief Executive Officer | Sale outside a trading plan | 537 | $28.69 | $15.4K | 254,878 | 24 Feb 2026 |
| 23 Feb 2026 | Burns Kristie, Sr. VP Mktg & Clinical Affairs | Sale outside a trading plan | 4,279 | $28.28 | $121.0K | 88,987 | 24 Feb 2026 |
| 23 Feb 2026 | Burns Kristie, Sr. VP Mktg & Clinical Affairs | Sale outside a trading plan | 160 | $28.69 | $4.6K | 88,827 | 24 Feb 2026 |
| 2 Jan 2026 | Burns Kristie, Sr. VP Mktg & Clinical Affairs | Sale under a trading plan | 5,139 | $28.85 | $148.3K | 72,401 | 6 Jan 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 20 Aug 2026 | William W Burke, board of director | 15,000 | $540.3M | 19 Aug 2026 |
| 10 Aug 2026 | Dodd Sheri Louise, Officer, Director | 10,978 | $323.2K | 10 Aug 2026 |
| 11 May 2026 | Birkemeyer Elaine M., Officer | 4,631 | $113.4K | 11 May 2026 |
| 25 Feb 2026 | Burns Kristie, Officer | 4,000 | $113.9K | 25 Feb 2026 |
| 24 Feb 2026 | Burns Kristie, Officer | 6,246 | $180.8K | 24 Feb 2026 |
| 24 Feb 2026 | Birkemeyer Elaine M., Officer | 7,701 | $222.9K | 24 Feb 2026 |
| 24 Feb 2026 | Dodd Sheri Louise, Officer, Director | 10,993 | $318.1K | 24 Feb 2026 |
| 23 Feb 2026 | Burns Kristie, Officer | 4,439 | $125.6K | 23 Feb 2026 |
| 23 Feb 2026 | Birkemeyer Elaine M., Officer | 5,518 | $156.1K | 23 Feb 2026 |
| 23 Feb 2026 | Dodd Sheri Louise, Officer, Director | 15,240 | $431.2K | 23 Feb 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Cadian Capital Management, LP | 13G amended | 7% | 1.6M |
| 12 Aug 2026 | Morgan Stanley | 13G amended | 3.7% | 829.7K |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Feb 2026 | Cadian Capital Management, LP | 13G amended | 4.9% | 1.1M |
| 12 Feb 2026 | PARADIGM CAPITAL MANAGEMENT INC/NY | 13G amended | 3.3% | 736.6K |
| 12 Feb 2026 | Morgan Stanley | 13G amended | 5.8% | 1.3M |
| 21 Jan 2026 | Dimensional Fund Advisors LP | 13G amended | 4.9% | 1.1M |
| 31 Oct 2025 | The Vanguard Group | 13G amended | 7.06% | 1.6M |
Trades by members of the House
From each member's periodic transaction report.
| Traded | Member | Type | Amount | Disclosed |
|---|---|---|---|---|
| 23 Jan 2019 | Donna Shalala (FL27) | Purchase | $1,001 - $15,000 | 27 Apr 2020 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.8M | -0.69% | 13.14 |
| 30 Sep 2026 | 2.8M | +1.22% | 9.85 |
| 15 Sep 2026 | 2.8M | +7.85% | 10.42 |
| 31 Aug 2026 | 2.6M | +2.3% | 7.74 |
| 14 Aug 2026 | 2.6M | +8.5% | 5.97 |
| 31 Jul 2026 | 2.4M | -4% | 11.47 |
| 15 Jul 2026 | 2.4M | +0.21% | 10.53 |
| 30 Jun 2026 | 2.4M | +6.02% | 7.82 |
Funds that hold it
From each fund's latest Form 13F.
211 funds held it at 30 Jun 2026: 106 added and 44 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 1,905,086 | $56.7M | +125,640 |
| Cadian Capital Management, LP | 1,576,940 | $47.0M | +535,868 |
| Dimensional Fund Advisors LP | 1,092,193 | $32.5M | +12,477 |
| Morgan Stanley | 979,340 | $29.2M | -403,472 |
| Vanguard Capital Management LLC | 970,246 | $28.9M | +25,149 |
| Driehaus Capital Management LLC | 937,783 | $27.9M | +195,869 |
| Acadian Asset Management LLC | 903,553 | $26.9M | -1,816 |
| Vanguard Portfolio Management LLC | 706,509 | $21.0M | +38,175 |
| Federated Hermes, Inc. | 681,153 | $20.3M | +20,196 |
| Arrowstreet Capital, Limited Partnership | 638,368 | $19.0M | 0 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B